

# Resource Summary Report

Generated by [nidm-terms](#) on Jul 28, 2026

## CalcuSyn

RRID:SCR\_020251

Type: Tool

### Proper Citation

CalcuSyn (RRID:SCR\_020251)

### Resource Information

**URL:** <http://www.biosoft.com/w/calculusyn.htm>

**Proper Citation:** CalcuSyn (RRID:SCR\_020251)

**Description:** Software tool for drug mixtures study and establishing efficacy. Dose effect analyzer of combined drugs. Able to quantify synergism and inhibition. CalcuSyn Version 2.0 has Undo and Redo tools.

**Synonyms:** CalcuSyn Version 2.0

**Resource Type:** software application, software resource, data processing software, data analysis software

**Keywords:** Biosoft, drug mixtures study, drug efficacy, dose effect, quantify synergism, quantify inhibition

**Availability:** Restricted

**Resource Name:** CalcuSyn

**Resource ID:** SCR\_020251

**Record Creation Time:** 20220129T080349+0000

**Record Last Update:** 20260728T043605+0000

### Ratings and Alerts

No rating or validation information has been found for CalcuSyn.

No alerts have been found for CalcuSyn.

### Data and Source Information

## Usage and Citation Metrics

We found 57 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [nidm-terms](#) .

Spender LC, et al. (2025) AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma. *British journal of cancer*, 133(5), 709.

Keser M, et al. (2025) Design, Synthesis, and Molecular Docking of Triazole-Coumarin Hybrids as Potent Breast Cancer Inhibitors Targeting Cell Cycle and Apoptosis. *Chemistry & biodiversity*, 22(12), e01775.

Meric-Bernstam F, et al. (2025) Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(3), 573.

Oh S, et al. (2025) The Synergistic Effect of PARP Inhibitors and Irinotecan in Small Cell Lung Cancer Cells. *Cancer research and treatment*, 57(4), 1040.

Anastasio G, et al. (2025) Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors. *iScience*, 28(2), 111842.

Araújo NM, et al. (2025) The antitumor effect of tlr4 inhibition in head and neck cancer cell lines. *Scientific reports*, 15(1), 31681.

Xing HB, et al. (2025) Resveratrol synergizes with cisplatin to suppress osteosarcoma U2-OS cells via up-regulating Cx43 and inducing ROS-dependent apoptosis. *Discover oncology*, 16(1), 2218.

Massa A, et al. (2025) Doxycycline Restores Gemcitabine Sensitivity in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma. *Cancers*, 17(1).

Melcón-Fernández E, et al. (2024) In Vitro and Ex Vivo Synergistic Effect of Pyrvinium Pamoate Combined with Miltefosine and Paromomycin against Leishmania. *Tropical medicine and infectious disease*, 9(2).

Chen SY, et al. (2024) Advancing Lung Cancer Treatment with Combined c-Met Promoter-Driven Oncolytic Adenovirus and Rapamycin. *Cells*, 13(18).

Bojkova D, et al. (2023) Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform. *iScience*, 26(2), 105944.

Li Y, et al. (2023) Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. *Journal of experimental & clinical cancer research : CR*, 42(1), 6.

Lee CL, et al. (2023) Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer. *Cancer biology & therapy*, 24(1), 2223388.

DiPeri TP, et al. (2023) Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(21), 4385.

Yang Z, et al. (2023) A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation. *EBioMedicine*, 92, 104594.

Vanaroj P, et al. (2023) Atractylodin and ?-eudesmol from *Atractylodes lancea* (Thunb.) DC. Inhibit Cholangiocarcinoma Cell Proliferation by Downregulating the Notch Signaling Pathway. *Asian Pacific journal of cancer prevention : APJCP*, 24(2), 551.

Centonze G, et al. (2023) p140Cap modulates the mevalonate pathway decreasing cell migration and enhancing drug sensitivity in breast cancer cells. *Cell death & disease*, 14(12), 849.

Melcon-Fernandez E, et al. (2023) Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of *Leishmania donovani* Visceral Leishmaniasis. *International journal of molecular sciences*, 24(2).

Wang X, et al. (2022) PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer. *Cell reports. Medicine*, 3(9), 100741.

Rong X, et al. (2022) Close association between the synergistic toxicity of zearalenone-deoxynivalenol combination and microRNA221-mediated PTEN/PI3K/AKT signaling in HepG2 cells. *Toxicology*, 468, 153104.